Why the study?
The expression pattern of claudin-18.2 in pancreatic ductal adenocarcinoma, especially the concordance between biopsy and resection specimens, was unknown.
What is the concordance of claudin-18.2 expression between biopsy, resection, and recurrent specimens in pancreatic ductal adenocarcinoma?
What is the concordance of claudin-18.2 expression between biopsy, resection, and recurrent specimens in pancreatic ductal adenocarcinoma?
Biopsy-based assessment of claudin-18.2 in pancreatic cancer has low sensitivity compared to resection specimens, potentially missing patients eligible for targeted therapy.
No takes yet. Share an insight, caveat, or question.
Biopsy may underdetect CLDN18.2-positive PDAC for zolbetuximab; leaves open confirmatory resection and cutoff optimization.
Kyuno et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: